M. Stahl

6.4k total citations · 2 hit papers
113 papers, 4.1k citations indexed

About

M. Stahl is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, M. Stahl has authored 113 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pulmonary and Respiratory Medicine, 72 papers in Surgery and 27 papers in Oncology. Recurrent topics in M. Stahl's work include Gastric Cancer Management and Outcomes (82 papers), Esophageal Cancer Research and Treatment (60 papers) and Metastasis and carcinoma case studies (25 papers). M. Stahl is often cited by papers focused on Gastric Cancer Management and Outcomes (82 papers), Esophageal Cancer Research and Treatment (60 papers) and Metastasis and carcinoma case studies (25 papers). M. Stahl collaborates with scholars based in Germany, Switzerland and France. M. Stahl's co-authors include H. Wilke, Martin Stuschke, Wilfried Budach, Martin K. Walz, Hans‐Joachim Meyer, Nils Lehmann, S. Seeber, Michael Bitzer, Jorge Riera‐Knorrenschild and Bodo Klump and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

M. Stahl

104 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus

2005 935 citations M. Stahl, Martin Stuschke et al. Journal of Clinical Oncology profile →
Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction

2009 654 citations M. Stahl, Martin K. Walz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Stahl Germany	28	3.2k	2.9k	860	484	241	113	4.1k
Johnathan Joffe United Kingdom	17	1.2k 0.4×	827 0.3×	835 1.0×	235 0.5×	305 1.3×	36	1.8k
Stephen R. Smalley United States	24	3.9k 1.2×	2.5k 0.9×	1.7k 1.9×	1.3k 2.7×	300 1.2×	52	5.4k
Wasat Mansoor United Kingdom	23	1.9k 0.6×	1.0k 0.4×	1.9k 2.2×	655 1.4×	340 1.4×	98	3.1k
Katrin Marie Sjoquist Australia	19	1.3k 0.4×	1.3k 0.5×	688 0.8×	113 0.2×	211 0.9×	85	2.1k
E. Maillard France	14	1.7k 0.5×	1.8k 0.6×	1.1k 1.2×	89 0.2×	331 1.4×	40	3.3k
Thor Alvegård Sweden	33	2.7k 0.8×	837 0.3×	1.6k 1.9×	377 0.8×	355 1.5×	81	3.3k
Tatsuo Matsuda Japan	19	716 0.2×	727 0.3×	781 0.9×	318 0.7×	207 0.9×	47	1.8k
Michael Leahy United Kingdom	27	2.0k 0.6×	1.2k 0.4×	1.8k 2.1×	263 0.5×	374 1.6×	70	3.4k
Harald Schmalenberg Germany	17	1.6k 0.5×	1.3k 0.5×	2.3k 2.7×	409 0.8×	309 1.3×	46	3.1k
Anthony H. Russell United States	35	2.6k 0.8×	2.9k 1.0×	1.6k 1.8×	66 0.1×	158 0.7×	90	4.8k

Countries citing papers authored by M. Stahl

Since Specialization

Citations

This map shows the geographic impact of M. Stahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Stahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Stahl more than expected).

Fields of papers citing papers by M. Stahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Stahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Stahl. The network helps show where M. Stahl may publish in the future.

Co-authorship network of co-authors of M. Stahl

This figure shows the co-authorship network connecting the top 25 collaborators of M. Stahl. A scholar is included among the top collaborators of M. Stahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Stahl. M. Stahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Thuss‐Patience, Peter, Eray Goekkurt, M. Stahl, et al.. (2024). Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma. JAMA Network Open. 7(1). e2352830–e2352830. 9 indexed citations

2.

Porschen, Rainer, Wolfgang Fischbach, Ines Gockel, et al.. (2023). S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Zeitschrift für Gastroenterologie. 61(6). 701–745. 1 indexed citations

3.

Lorenzen, Sylvie, Claudia Pauligk, Eray Goekkurt, et al.. (2023). Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer. 23(1). 561–561. 5 indexed citations

4.

Lordick, Florian, Salah‐Eddin Al‐Batran, Dirk Arnold, et al.. (2023). German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer. 27(1). 6–18. 3 indexed citations

5.

Porschen, Rainer, Wolfgang Fischbach, Ines Gockel, et al.. (2023). S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Zeitschrift für Gastroenterologie. 61(6). e209–e307.

6.

Baretton, Gustavo, Florian Lordick, Timo Gaiser, et al.. (2023). Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. Journal of Cancer Research and Clinical Oncology. 149(17). 16231–16238. 6 indexed citations

7.

Panje, Cédric, Stefanie Hayoz, Wolfgang Eisterer, et al.. (2022). Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. European Journal of Cancer. 177. 186–193. 2 indexed citations

8.

Gencer, Deniz, Andreas Schneeweiß, H. Schulz, et al.. (2014). PROCAPP: A randomized, open-label phase III trial comparing mapisal and urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot skin reaction (HFSR) in patients (pts) with gastrointestinal (GI) tumors or breast cancer—A study of the AIO Quality of Life Working Group.. Journal of Clinical Oncology. 32(15_suppl). 9631–9631. 1 indexed citations

9.

Stahl, M.. (2012). Multimodal Therapy of GEJ Cancer: When is the Definitive Radiochemotherapy the Treatment of Choice?. Recent results in cancer research. 196. 181–185.

10.

Stahl, M., Bernd J. Krause, Luigi Bonavina, et al.. (2011). Curative treatment of oesophageal carcinoma: current options and future developments. Radiation Oncology. 6(1). 55–55. 27 indexed citations

11.

Stahl, M. & Júlio Oliveira. (2009). Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology. 20. iv32–iv33. 28 indexed citations

12.

Wilke, H., N. Willich, Hans‐Joachim Meyer, & M. Stahl. (2008). Neoadjuvante und perioperative Therapie des Magenkarzinoms. Der Onkologe. 14(4). 370–380. 1 indexed citations

13.

Stahl, M., Vesa Kataja, & Júlio Oliveira. (2005). ESMO Minimal Clinical Recommendations for diagnosis, treatment and follow-up of esophageal cancer. Annals of Oncology. 16. i26–i27. 4 indexed citations

14.

Stuschke, Martin, M. Stahl, H. Wilke, et al.. (2004). Randomized phase III trial in locally advanced squamous cell carcinoma of the esophagus: Neoadjuvant radiochemotherapy followed by surgery vs. definitive radiochemotherapy. International Journal of Radiation Oncology*Biology*Physics. 60(1). S139–S139. 1 indexed citations

15.

Stahl, M., H. Wilke, Martin K. Walz, et al.. (2004). Randomized phase III trial in locally advanced squamous cell carcinoma of the esophagus: Neoadjuvant radiochemotherapy followed by surgery vs. definitive radiochemotherapy. International Journal of Radiation Oncology*Biology*Physics. 60. S139–S139. 2 indexed citations

16.

Sarbia, Mario, M. Stahl, U. Fink, et al.. (1999). Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. International Journal of Cancer. 84(1). 86–91. 55 indexed citations

17.

Stahl, M., U. Vanhoefer, U. Fink, et al.. (1996). Phase II Study of Weekly High-Dose 5-Fluorouracil and Folinic Acid plus Biweekly Alternating Cisplatin and Epirubicin (FUFACE) in Patients with Advanced Gastric Carcinoma. Oncology Research and Treatment. 19(5). 416–418. 6 indexed citations

18.

Wilke, H., P. Preusser, M. Stahl, et al.. (1994). Phase II Study with Folinic Acid, Etoposide, 5-Fluorouracil and Cisplatin (FLEP) for Advanced Gastric Cancer. Oncology Research and Treatment. 17(2). 154–157.

19.

Harstrick, A., Carsten Bokemeyer, Andreas Mügge, et al.. (1993). Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 72(7). 2242–2247. 89 indexed citations

20.

Stahl, M., H. Wilke, P. Preusser, et al.. (1991). Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk. Oncology Research and Treatment. 14(4). 314–318. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact